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Abstract. Chronic prostatitis/chronic pelvic pain syndrome 
(CP/CPPS) is a complex condition for which the etiological 
determinants are still poorly defined. To better characterize 
the diagnostic and therapeutic profile of patients, an algorithm 
known as UPOINT was created, addressing six major phenotypic 
domains of CP/CPPS, specifically the urinary (U), psycho‑social 
(P), organ‑specific (O), infection (I), neurological/systemic (N) 
and muscular tenderness (T) domains. An additional sexual 
dysfunction domain may be included in the UPOINT(S) system. 
The impact of the infection domain on the severity of CP/CPPS 
symptoms is a controversial issue, due to the contradictory 
results of different trials. The aim of the present retrospective 
study was to further analyze the extent to which a positive 
infection domain of UPOINTS may modify the pattern of 
CP/CPPS symptom scores, assessed with the National Institutes 
of Health‑Chronic Prostatitis Symptom Index (NIH‑CPSI). In 
a cohort of 935 patients that was divided on the basis of the 
presence or absence of prostatic infection, more severe clinical 
symptoms were shown by the patients with infection (median 
NIH total score: 24 versus 20 points in uninfected patients; 
P<0.001). Moreover, NIH‑CPSI score distribution curves were 
shifted towards more severe symptoms in patients with a posi-
tive infection domain. Division of the patients into the six most 
prominent phenotypic clusters of UPOINTS revealed that the 
‘prostate infection-related sexual dysfunction’ cluster, including 
the highest proportion of patients with evidence of infection 
(80%), scored the highest number of NIH‑CPSI points among 
all the clusters. To assess the influence of the infection domain 
on the severity of patients' symptoms, all subjects with evidence 
of infection were withdrawn from the ‘prostate infection-related 
sexual dysfunction’ cluster. This modified cluster showed 
symptom scores significantly less severe than the original 
cluster, and the CPSI values became comparable to the scores 
of the five other clusters, which were virtually devoid of patients 
with evidence of infection. These results suggest that the pres-
ence of pathogens in the prostate gland may significantly affect 
the clinical presentation of patients affected by CP/CPPS, and 
that the infection domain may be a determinant of the severity 
of CP/CPPS symptoms in clusters of patients phenotyped with 
the UPOINTS system. This evidence may convey considerable 
therapeutic implications.
Introduction
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) 
is a complex condition for which the etiological determi-
nants are still poorly defined. Its prevalence ranges between 
2.2 and 13.8%, depending on specific populations, countries 
and surveys (1,2). CP/CPPS is characterized by a wide array 
of symptoms, including pain in the pelvic region, irritative 
and/or obstructive voiding symptoms, other pelvic distur-
bances, sexual dysfunction and psycho‑social maladjustment 
amongst others (3).
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Due to the fact that every patient with CP/CPPS presents a 
unique, individual profile of symptoms defining the syndrome, 
phenotypic characterization is required to profile the clinical 
features of each single subject, and to direct symptomatic 
therapy. For this reason, a novel diagnostic/therapeutic algo-
rithm known as UPOINT was created, addressing six major 
phenotypic domains of CP/CPPS, specifically the urinary (U), 
psycho-social (P), organ-specific (O), infection (I), neuro-
logical/systemic (N) and muscular tenderness (T) domains. 
UPOINT, with or without an additional domain addressing 
sexual dysfunction (‘UPOINTS’), has been initially validated 
in two cohort studies, performed on North-American (4) and 
European patients (5).
The major finding of the first North‑American validation 
study was the correlation between the number of UPOINT 
domains and the total score of the National Institutes of 
Health-Chronic Prostatitis Symptom Index (NIH-CPSI) 
measured in each patient (4). Whereas a strong correlation was 
also observed in the European cohort (5), certain discrepan-
cies between the two studies were evident. In the study by 
Shoskes et al, the severity of the symptoms in the patients with 
a positive infection domain was not significantly different 
from the symptom scores of patients without evidence of 
prostatic infection (4). Conversely, in the study by Magri 
et al, patients with a positive infection domain showed higher 
symptom scores, measured using the NIH‑CPSI (5). This 
suggested the existence of different populations of patients, 
exhibiting different degrees of symptom severity, depending 
on the presence or absence of infection. Recently, we have 
investigated the distribution of NIH‑CPSI symptom scores in 
a large cohort of patients from different countries globally (6). 
Graphic representations of the total NIH‑CPSI symptom score 
distributions showed irregular patterns (6), possibly due to 
multiple overlapping peaks, which suggested the existence of 
different subpopulations of patients showing various degrees 
of symptom severity.
In the present study, we report the results of a retrospective 
analysis of a population of 935 Italian patients who had been 
included in the large international studies mentioned previ-
ously (5,6). The aim of the present study was to investigate 
in greater detail the extent to which a positive UPOINTS 
infection domain may modify the distribution patterns of 
NIH‑CPSI symptom scores in this patient population.
Patients and methods
Clinical database. The present retrospective observational 
study was performed on a database of 935 Italian patients, 
representing a subset of a total population of 1,563 subjects 
from Europe and North America enrolled in two recent, ethi-
cally approved international studies investigating NIH-CPSI 
and the UPOINT(S) system (5,6). This subset of patients 
was diagnosed and treated by one urologist (VM) in a single 
specialized, second referral prostatitis center in Italy (Urology 
and Urological Sonography Secondary Care Clinic, Azienda 
Ospedaliera Istituti Clinici di Perfezionamento, Milan). 
Patients provided written consent for the handling and anony-
mous publication of their data. 
The database used for this subset analysis included 
demographic data, diagnosis [CP/CPPS, category IIIa (inflam-
matory) versus IIIb (non‑inflammatory)], UPOINT phenotypes 
and the scores of the NIH‑CPSI questionnaire.
Inclusion criteria and diagnostic procedures. CP/CPPS was 
diagnosed according to the NIH criteria (7). Inclusion/exclu-
sion criteria for the study, as well as the items by which patients 
were allocated as positive for the individual UPOINT domains, 
have been described in the main study report (5). Exclusion 
criteria included a diagnosis of acute or chronic bacterial pros-
tatitis (CBP; NIH categories I or II, NIH criteria) (7). 
The presence of bacteria or pathogens in the prostate was 
assessed with the ‘4-glass’ lower urinary tract segmented test 
according to Meares and Stamey, based on the collection 
and culture of i) first‑voided (VB1), ii) midstream (VB2) and 
iii) post‑massage voided urine (VB3) specimens, and iv) of 
expressed prostatic secretions (EPS) collected during prostatic 
massage (8). A one‑log ratio between bacterial counts in VB3 
versus VB2 or VB1 was the cutoff value defining “prostatic 
infection (8) and a positive UPOINTS infection domain.. 
CP/CPPS symptoms were evaluated by asking the patients 
to complete the NIH-CPSI questionnaire, an internationally 
validated clinical tool measuring disease symptoms and 
characteristics (9). The NIH‑CPSI measures combined aspects 
of the three most important symptom domains of CP/CPPS, 
with higher scores indicating higher disease severity. These 
symptom domains include pain (location, frequency and 
severity; score range, 0 to 21), voiding problems (irritative and 
obstructive symptoms; score range, 0 to 10), and impact of the 
disease on the quality of life of patients (QoL; score range, 0 to 
12), with a total score ranging from 0 to 43.
Statistics. χ2 analysis was used to evaluate differences in the 
proportions of patients with and without a positive infection 
domain for each score of the NIH-CPSI questionnaire (total 
score, and pain, void and QoL sub‑scores).
The median was used as a measure of central tendency for 
the scores and sub‑scores of the NIH‑CPSI. The upper and lower 
quartiles were calculated to evaluate the dispersion of the data. 
The Mann‑Whitney‑Wilcoxon test was used to analyze unpaired 
differences in NIH‑CPSI scores between patient groups.
Due to its large sample size, the present study was 
adequately powered (1-β=90%) to detect clinically relevant 
changes (6 points) in the total scores of the NIH-CPSI, with a 
5% α error probability. The results of all statistical tests were 
considered significant in the presence of an α error <0.05. Data 
were analyzed with the XLStatistics 5.71 program (©Rodney 
Carr; http://www.deakin.edu.au/~rodneyc/).
Results
NIH-CPSI scores and distribution patterns in patients with 
or without evidence of infection. Fig. 1 shows the distribution 
pattern of total NIH-CPSI scores in the total CP/CPPS patient 
population. The distribution appears to be non‑unimodal and 
slightly right‑skewed (moment coefficient of skewness, 0.11: 
‘approximately symmetric’ by definition). Table I shows the 
median values of the NIH-CPSI total score and symptom 
domain subscores, and the statistical analysis of the differ-
ences between cohorts of patients with or without evidence 
of prostatic infection (i.e. a positive or negative UPOINTS 
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infection domain, respectively). The pain and QoL subdomain 
scores, and the total score of the NIH‑CPSI were significantly 
different between these cohorts. The voiding symptom scores 
of the NIH‑CPSI did not differ between cohorts.
Fig. 2 shows the distribution patterns of NIH‑CPSI scores 
in patients with a positive or negative infection domain of the 
UPOINTS phenotyping system. In the graph showing the 
pain domain (Fig. 2A), the distribution pattern of patients 
with a positive infection domain is shifted to the right, i.e. 
toward more severe pain symptom scores. Significantly higher 
proportions of patients with infection showed symptom scores 
as high as 13-17, compared with patients showing no evidence 
of bacterial infection in the prostate.
Since the pain domain is the component of greater weight 
in the NIH‑CPSI scoring system, the previously described 
difference between ‘infected’ versus ‘non-infected’ patients 
is reflected in the distribution of the NIH‑CPSI total scores, 
as shown in Fig. 2D. At symptom scores >27, patients with 
a positive infection domain were predominantly present in 
significantly higher proportions, compared with subjects 
without evidence of infection. These differences were less 
evident in the two other sections of the NIH‑CPSI test, i.e. 
the voiding and QoL domains. However, significantly higher 
numbers of infected patients were still observed at higher 
scores in these two domains (Fig. 2B and C).
Impact of infection on NIH-CPSI scores in phenotypic clusters 
of CP/CPPS patient. Since the distribution of data shown in 
Fig. 2 indicated the existence of two distinct populations with 
differing symptom scores, and due to the fact that infection 
was the discriminant element in this respect, we investigated 
whether it was also possible to observe these differences in the 
CP/CPPS phenotype clusters reported by Davis et al in their 
recent UPOINT(S) cluster analysis (10). In this previous study, 
it was shown that patients with CP/CPPS tended to segregate 
into six different clusters, each containing patients showing 
high frequencies of specific UPOINTS domains (10). These 
clusters were denominated: i) prostate infection-related sexual 
dysfunction (high frequencies of O, I and S domains); ii) wide-
spread symptoms (high frequencies of U, O and N domains); 
iii) psychosocially complex lower urinary tract symptoms 
(LUTS) with sexual dysfunction (high frequencies of P and 
S domains); iv) psychosocially complex LUTS without sexual 
dysfunction (high frequencies of U and P domains); v) muscle 
tenderness/fibromyalgia‑like symptoms (high frequency of T 
domain) and vi) uncomplicated LUTS (increased frequencies 
of U and O domains). The infection domain of the UPOINT 
system was present at very high frequency (80% of patients) 
only in the first cluster.
NIH‑CPSI scores were calculated subsequent to the classifi-
cation of the present patient population according to the clusters 
described by Davis et al (10). As shown in Table II, patients 
belonging to the ‘prostate infection-related sexual dysfunction’ 
cluster showed significantly higher pain, voiding symptom, 
QoL and total scores of the NIH-CPSI, compared with all other 
clusters. Table II also shows that the scores of a modified group, 
i.e. the ‘prostate infection-related sexual dysfunction’ cluster 
lacking all patients with evidence of infection, were signifi-
cantly lower than the ones shown by the original cluster, and 
were virtually equivalent to those shown by the other clusters, 
which were also lacking high proportions of infected patients.
Table I. Median values of the NIH‑CPSI total score and symptom domain subscores, and statistical analysis of differences between 
cohorts of patients with category III CP/CPPS with or without evidence of prostatic infection, defined according to NIH criteria (7).
 Total patient Patients with Patients without
 population evidence of infection evidence of infection
 ---------------------------------------------------- ------------------------------------------------------ -----------------------------------------------------
  Upper and  Upper and  Upper and
NIH-CPSI score Median lower quartiles Median lower quartiles Median lower quartiles
1 - pain domain   9   7-12 11  8-14   9a 7-11
2 - voiding symptom domain   4 2-6   4 2-7   4b 2-6
3 - QoL impact domain   8 5-9   8 6-10   7a 5-9
Total score (1+2+3) 21 16-26 24 18-29 20c 15-24
aP<0.01 vs. patients with evidence of infection, Mann‑Whitney‑Wilcoxon test; bP>0.05 vs. patients with evidence of infection, 
Mann‑Whitney‑Wilcoxon test; cP<0.001 vs. patients with evidence of infection, Mann‑Whitney‑Wilcoxon test. NIH‑CPSI, National Institutes 
of Health‑Chronic Prostatitis Symptom Index; CP/CPPS, chronic prostatitis/chronic pelvic pain syndrome; QoL, quality of life.
Figure 1. Distribution pattern of total National Institutes of Health‑Chronic 
Prostatitis Symptom Index (NIH-CPSI) scores in the chronic prosta-
titis/chronic pelvic pain syndrome (CP/CPPS) patient population analyzed in 
this study. The vertical axis shows the total number of patients with a specific 
NIH‑CPSI score.
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Discussion
Category III CP/CPPS, and its inflammatory and non‑inflam-
matory (categories IIIa and IIIb, respectively) variants, have 
been originally defined, diagnosed and investigated as a 
chronic prostatitis syndrome involving pelvic pain and voiding 
symptoms in the presence of sterile microbiological cultures 
of expressed prostatic secretions and/or urine specimens 
following prostatic massage (11). Over time, this original defi-
nition has evolved, and experts have proposed a model whereby 
the prostate of patients with CP/CPPS may be colonized by a 
variety of organisms, including either traditional uropathogens 
(such as E.coli, Klebsiella spp., other Enterobacteriaceae 
and Enterococci), viz the etiological agents of acute and 
Figure 2. Distribution patterns of National Institutes of Health‑Chronic Prostatitis Symptom Index (NIH‑CPSI) scores in patients with a positive (black bars) 
or negative (empty bars) infection domain of the UPOINTS system [i.e. patients with positive or negative microbiological cultures of expressed prostatic 
secretions (EPS) and/or post‑massage voided urine (VB3) specimens from a standard ‘4‑glass’ test according to Meares and Stamey (8)]. (A) Pain domain; 
(B) voiding symptom domain; (C) impact on quality of life (QoL) domain; (D) total NIH‑CPSI score. The vertical axes show the percentages of patients with 
a specific symptom score per‑group (infection group vs. no infection group). The comparison between proportions of patients showing the same score in the 
two groups was performed using the χ2 test. *P<0.05.
  A   B
  C   D
Table II. Median values (and interquartile range) of the NIH‑CPSI total score and symptom domain subscores, and statistical 
analysis of differences between cohorts of patients with category III CP/CPPS divided by cluster according to Davis et al (10). 
Median scores of group ‘1*’, a subgroup of cluster 1 devoid of patients showing evidence of infection, defined according to NIH 
criteria (7), are also presented.
 Cluster classification
 ------------------------------------------------------------------------------------------------------------------------------------------------------------------
NIH-CPSI score 1 1* 2 3 4 5 6
1 - pain domain 12 (5) 9a (4) 9a (5) 9a (5) 10a (4) 10a (4) 9a (5)
2 ‑ voiding symptom domain 6 (3.75) 5a (2.00) 4a (4.00) 4a (4.00) 6b (2.00) 4a (4.00) 5a (4.00)
3 - QoL impact domain 9 (4) 8a (3) 8a (3) 8a (3) 9b (4) 8a (4) 8a (3)
Total score (1+2+3) 28 (9.75) 22a (9.00) 21a (10.00) 22a (9.00) 24a (7.50) 22a (10.00) 22a (9.00)
Cluster classification, according to Davis et al (10): 1, prostate infection-related sexual dysfunction; 1*, same as ‘1’, but with the withdrawal of 
patients showing evidence of infection; 2, widespread symptoms; 3, psychosocially complex lower urinary tract symptoms (LUTS) with sexual 
dysfunction; 4, psychosocially complex LUTS without sexual dysfunction; 5, muscle tenderness/fibromyalgia‑like symptoms; 6, uncompli-
cated LUTS. aP<0.01 vs. cluster 1, Mann‑Whitney‑Wilcoxon test; bP<0.05 vs. cluster 1, Mann‑Whitney‑Wilcoxon test. NIH‑CPSI, National 
Institutes of Health‑Chronic Prostatitis Symptom Index; CP/CPPS, chronic prostatitis/chronic pelvic pain syndrome; QoL, quality of life.
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chronic bacterial prostatitis, or bacteria causing disease in 
other distant or adjacent organs (including coagulase-negative 
Staphylococci, Streptococci, Chlamydia trachomatis and 
Mycoplasmata) that have not yet been unanimously classi-
fied as prostatic pathogens (12). This model, also based on 
the results of a study showing similar infection frequencies 
in symptomatic versus asymptomatic patients, has led to a 
tentative definition of ‘bacterial CP/CPPS’ (13: see reply to 
published letter).
According to this theory, these bacteria do not act as deter-
minants of pathogenicity in category III CP/CPPS. Instead, they 
represent ‘bystander flora’, whose pharmacological eradication 
would not be likely to result in symptom remission. Using this 
model, a diagnosis of category II CBP is only possible in cases 
of a documented history of relapsing episodes of urinary tract 
infections (UTIs) originating from an infected prostate. This 
concept has led to the inclusion of an infection domain into the 
UPOINT algorithm, a system recently proposed to improve 
the phenotypic profiling of patients with CP/CPPS (4).
However, this concept has not been unanimously applied in 
clinical practice, and other clinicians and scientists have main-
tained that the presence of pathogens in the prostatic secretions 
of chronically symptomatic patients may be etiologically 
linked to the clinical manifestation of category II CBP, even in 
the absence of a long, documented history of repeated flare‑ups 
of the infection (14,15). According to this view, a symptom-
atic episode of clinical chronic prostatitis with evidence of 
uropathogens in the prostate may represent the initial phase of 
a history of CBP, and there is therefore a requirement for it to 
be diagnosed and treated accordingly. Antibacterial treatment 
of such patients has been associated with symptom remission 
in numerous cases (14,15). For clarity, it is necessary to state 
that in the present study CP/CPPS was diagnosed according 
to the ‘bystander flora’ hypothesis, and patients not showing 
a documented history of repeated episodes of UTIs stemming 
from a chronically infected prostate were classified as being 
affected by category III CP/CPPS.
In the first validation study by the authors who proposed 
the new UPOINT system, there was a failure to demonstrate 
the influence of pathogens cultured in prostate‑specific speci-
mens on CP/CPPS clinical symptoms, as assessed using the 
NIH‑CPSI questionnaire (4). By contrast, data obtained by our 
research group suggested that the presence of microorganisms 
may influence the severity of clinical symptoms of CP/CPPS. 
In patients showing evidence of infection at the prostatic level, 
the mean total NIH‑CPSI symptom scores were significantly 
increased by ~20% (5), when compared with scores from 
uninfected patients. This was demonstrated in a cohort of 
937 individuals, predominantly second referral Italian patients; 
however, it was not observed in second referral German 
patients (5). Notably, the difference observed in the second 
referral patients has been recently demonstrated by a prospec-
tive study performed on a cohort of ~400 Chinese patients, 
further validating the modified UPOINTS system (16). In 
addition, the mean total NIH-CPSI symptom scores in the 
Chinese cohort were increased by 20‑25% in patients with a 
positive infection domain of the UPOINTS system, including 
a sexual dysfunction domain (16).
Since this evidence suggests that the presence of pathogens 
is correlated with the deterioration of CP/CPPS symptoms, the 
present subset study analyzed in greater detail the symptom 
profile of a cohort of patients with CP/CPPS who had previ-
ously been included in two studies aimed at investigating the 
NIH-CPSI in patients with CP/CPPS, and at validating the 
UPOINT algorithm (5,6).
The patients were divided into two groups, depending on 
whether the prostate‑specific specimens of patients symptom-
atic for CP/CPPS were positive or negative for cultures. The 
median NIH‑CPSI scores, as well as pain and QoL subdomain 
scores, were significantly higher in the patients with a positive 
UPOINT infection domain, compared with patients with no 
evidence of infection (Table I). An exception was represented 
by the voiding score of NIH‑CPSI, which is known to be the 
least responsive among all NIH‑CPSI domains.
Despite the large size of the present patient population, 
which made the clinical relevance of the statistical significance 
of these differences debatable, the statistically significant, 
4‑point difference observed between the ‘infection’ and the 
‘non-infection’ groups (median scores, 24 versus 20 points; 
Table I) corresponded to the commonly accepted minimum 
value of a clinically appreciable difference in total NIH‑CPSI 
scores (17).
Notably, the analysis of symptom score distributions 
resulted in a right-shift of the curve representing pain symp-
toms and total NIH-CPSI scores in patients with evidence of 
prostatic infection (Fig. 2A and D). This evidence suggested 
the existence of populations showing different degrees of 
symptom severity, depending on the presence/absence of a 
concomitant prostatic infection.
Data from of a historical cohort of 157 Hellenic patients 
from our research group supported this finding: Patients 
showing the presence of pathogens in prostate‑specific speci-
mens (assessed with the Meares and Stamey segmented test) 
had higher NIH-CPSI symptom scores, compared with patients 
without evidence of infection (NIH-CPSI total score median 
difference: 7 points; P<0.0001, Mann‑Whitney‑Wilcoxon test; 
analysis not shown).
Subsequently, it was investigated whether it was possible to 
reproduce differential symptom scores in the two populations 
(infected versus non-infected) when the patient population was 
divided according to the six phenotypic clusters of patients 
with CP/CPPS, as described by Davis et al (10). The ‘prostate 
infection-related sexual dysfunction’ cluster, including the 
highest proportion of patients with evidence of infection (80%), 
scored the highest number of points of the NIH‑CPSI among 
all the clusters. To assess the influence of the infection domain 
on the severity of the symptoms exhibited by the patients, all 
subjects with evidence of infection were withdrawn from the 
prostate ‘infection-related sexual dysfunction’ cluster. This 
modified cluster showed symptom scores significantly less 
severe than those of the original cluster. Furthermore, the 
scores were comparable with those of the five other clusters.
Another recent study investigated the separation of patients 
with CP/CPPS into distinct phenotype clusters (18). According 
to this study, it was possible to divide the patients into two 
major clusters. One cluster included patients with increased 
frequencies of U, O and T domains, while the other showed 
a high frequency of P, I and N domains of UPOINT [notably, 
the ‘UOT’ cluster in our study cohort represented the most 
prominent group of patients (data not shown)]. Separation 
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of the present patient population into the ‘UOT’ and ‘PIN’ 
clusters resulted in significantly higher NIH‑CPSI symptom 
scores in the latter cluster (median total NIH-CPSI scores: 
29 versus 25 in the ‘UOT’ cluster; P<0.05, Mann‑Whitney 
Wilcoxon test), which contained higher proportions of subjects 
showing evidence of infection (detailed analysis not shown). 
Furthermore, when patients with evidence of infection were 
withdrawn from the cluster, NIH-CPSI scores decreased 
significantly [median total NIH-CPSI score: 24 (detailed 
analysis not shown)].
In combination, the results of the present study strength-
ened the hypothesis that the presence of pathogens in the 
prostate gland may exert a significant effect on the clinical 
presentation of patients affected by CP/CPPS, and that the 
UPOINTS infection domain represents an important deter-
minant of the severity of CP/CPPS symptoms in clusters of 
patients characterized by a positive infection domain of the 
UPOINTS system. This evidence implies that, if pathogens are 
partly responsible for a deterioration of symptoms in CP/CPPS, 
antibacterial agents may represent an important therapeutic 
tool for the treatment of patients showing evidence of prostate 
colonization by uropathogens or by other suspiciously patho-
genic bacteria. A retrospective analysis is in progress and a 
prospective study is being planned to assess the efficacy of 
antibacterial therapy in this specific category of patients.
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